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a subsequent valuation study to derive utility values for DR.
METHODS: Health state descriptions of visual acuity (VA) loss
were developed based on the ﬁndings of in-depth interviews with
diabetelogists and ophthalmologists. They represented visual
acuity levels in the best corrected eye (6/6-6/9, 6/12-6/18, 6/24-
6/36, 6/60-6/120, counting ﬁngers and hand motions). Two DR
patients in each VA level (N = 10) and members of general public
(N = 10) took part in standard gamble (SG) interviews and a
cognitive debrief interview. The interview attempted to explore
participants’ preferences around aspects of the health states. SG
data were summarised and transcribed interviews underwent
qualitative analysis of content. Qualitative data analysis
attempted to explore the rationale for SG valuations and the dif-
ferences in patient and public preferences. RESULTS: SG data
showed that patients value vision loss and its impact on health-
related quality of life differently to members of the general
public. This was further supported by the ﬁndings of the quali-
tative interviews in which patients’ provided personal insight
into their own experience of the disease and its impact on their
health-related quality of life. Qualitative analysis illustrated the
different perceptions of health states. CONCLUSION: The dif-
ferences in patients’ and societal views of vision loss associated
with DR and its impact on functioning were explored. Valuable
insights were gained into the signiﬁcant determinants of patient
and public preferences which have implications for valuation
studies. This information will be particularly important in under-
standing the decision making process that drives people’s choice.
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OBJECTIVES: This study evaluated the experience of hypo-
glycemia and its impact on QoL among diabetic patients treated
with MF in combination with a SU in France. METHODS: This
is an observational, cross sectional multi-center survey con-
ducted in 2005. Diabetic patients (≥35 years old) treated with
MF in combination with SU for ≥6 months prior to study enroll-
ment were included. Excluded were patients receiving insulin,
treated for hepatitis or HIV, or having gestational diabetes. Case
report forms were developed for collection of patients’ medical
record, experience of hypoglycemia, and general QoL as mea-
sured by EQ-5D. The un-weighted scoring rule was used to
obtain summary EuroQoL scores. Adjusted linear regression
analysis was used to evaluate the effect of hypoglycemia on
patients’ QoL controlling for demographic and medical charac-
teristics. RESULTS: Four-hundred patients were recruited:
average age was 62 years and 46% were female; 45% of the
patients have been diagnosed with diabetes for >7 years. One-
hundred-thirty-six (34%) patients reported at least one episode
of hypoglycemia during the previous 6 months: 79 (58%) expe-
rienced mild/moderate symptoms, 53 (39%) had both mild/mod-
erate and severe symptoms, and the remaining 3% had only
severe symptoms. More than half of those reported mild/mod-
erate symptoms, and >33% of those reported severe symptoms
had ≥3 hypoglycemic episodes during the 6-month period prior
to study enrollment. Patients with hypoglycemic episodes
reported signiﬁcantly lower EuroQoL scores relative to those
without any symptoms (0.7 vs. 0.8, p < 0.0001). After adjusting
for demographic and medical characteristics (age, gender, marital
status, education, co-morbid conditions) the reduction in the
EuroQoL score for those with any hypoglycemic symptoms was
0.08 (p = 0.0007) units. CONCLUSIONS: More than a third of
the study patients experienced one or more hypoglycemic symp-
toms. This study found that presence of hypoglycemic symptoms
is signiﬁcantly associated with lower QoL.
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OBJECTIVES: Hypoglycaemia is one of the most frequent acute
complications of type 1 diabetes. The fear and anxiety associ-
ated with experiencing hypoglycaemia may cause some diabet-
ics to deliberately allow their blood sugar to become elevated 
in order to avoid future events, thus risking long-term diabetic
complications. This trade-off between risks suggests that the psy-
chological impact of hypoglycaemia on quality of life may be
underestimated. This study’s prupose is to quantify the impact
of fear of hypoglycaemia on quality of life. METHODS: Eighty-
ﬁve type 1 diabetics completed the Hypoglycaemia Fear Survey
(HFS), and questions relating to the frequency and severity of
hypoglycaemic events. Respondents were categorised by whether
or not they had experienced a severe hypoglycaemic event in the
past three months. Key differences on the HFS were used to con-
struct ﬁve health states which described the behaviour, state of
mind and events experienced during a typical week for a type 1
diabetic: baseline; fear of non-severe hypoglycaemia with and
without a non-severe hypoglycaemic event; fear of severe hypo-
glycaemia with and without a severe hypoglycaemic event. A
total of 122 people from the general population evaluated the
ﬁve health states using the time-trade-off methodology. Short-
term disutilities during events and long-term disutilities due to
fear of future events were estimated as the differences between
health state utilities. RESULTS: Fear of severe hypoglycaemia
had a disutility value of −0.06 and fear of non-severe hypogly-
caemia had a disutility value of −0.01. A severe hypoglycaemic
event had a disutility value of −0.16, whilst the disutility associ-
ated with a non-severe hypoglycaemic event was −0.07. CON-
CLUSIONS: Fear of hypoglycaemia has a detrimental impact on
quality of life in diabetic patients beyond that of the event itself.
When comparing insulin therapies, the reduction in the incidence
of hypoglycaemia should be incorporated as an important
measure of treatment success.
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OBJECTIVE: To validate into Spanish and recalibrate the D-
FISQ, a 30-items 2-dimensions [Fear of self-injecting (FSI) and
self-testing (FST)], speciﬁc questionnaire for evaluating the fear
of injecting and self-testing in diabetic patients. METHODS:
Forward-backward translations in duplicate were carried out by
professional translators and revised by expert and non-expert
panels. Type 1 and 2 diabetic patients, both genders above 18
years were enrolled in 3 primary care centres. Spanish D-FISQ
